TrialClinical pharmacology and therapeutics2013

Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer.

J R Colca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.